| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AS605240 | GDSC1000 | pan-cancer | AAC | 0.14 | 9e-05 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.14 | 0.0001 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0001 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0002 |
| mRNA | ZG-10 | GDSC1000 | pan-cancer | AAC | 0.17 | 0.0002 |
| mRNA | TG-101348 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0002 |
| mRNA | AICAR | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0002 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0002 |
| mRNA | pac-1 | GDSC1000 | pan-cancer | AAC | -0.14 | 0.0002 |
| mRNA | VER-155008 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0003 |